摘要
目的为探讨TSGF、CYFRA21-1、NSE和D-D联合检测对肺癌的诊断价值。方法采用电化学发光技术和免疫比浊技术检测62名对照组、55例肺良性疾病组和141例肺癌组患者血清TSGF、CYFRA21-1、NSE和血浆D-D含量,并对单项和组合项诊断肺癌的敏感性,特异性和准确性和肺癌的临床分组进行比较,并探讨其联合检测意义。结果肺癌组患者血清TSGF(77.50±11.83U/mL)、CYFRA21-1(13.67±5.52g/L)、NSE(19.82±11.25g/L)和D-D(3.42±1.15mg/L)含量明显高于肺良性疾病组和对照组,差异有统计学意义(P<0.01)。结论血清TSGF、CYFRA21-1、NSE和D-D联合检测有助于提高肺癌诊断的敏感性、准确性,是筛查肺癌的一种简单、有效的检测方法。
Objective To explore the diagnostic value of combined detection of TSGF, CYFRA21-1, NSE and D-D in lung cancer. Methods The serum levels of TSGF, CYFRA21-1, NSE and plasma D-D content in 55 patients with pulmonary benign disease, 141 cases of patients with lung cancer and 62 health controls were de- tected by electrochemical luminescence and immune turbidity technology. The diagnosis sensitivity, specificity and accuracy by single of combination of detection were analyzed. Results The serum TSGF （77.5 ＋ 11.83 U/ mL）, CYFRA21-1 （13.67 ＋5.52g/L）, NSE （19.82 ＋ll.25g/L） and D-D （3.42 -＋1.15 mg/L） in the patients with lung cancer group were significantly higher than that of lung benign disease group and control group （P 〈0.01）. Conclusion The combined detection of TSGF, CYFRA21-1, NSE and D-D could improve the sensitivity and accuracy, and might be a simple and effective detection method in lung cancer screening.
出处
《标记免疫分析与临床》
CAS
2012年第4期201-204,共4页
Labeled Immunoassays and Clinical Medicine
